Research Article

Chemical Profiling of an Antimigraine Herbal Preparation, Tianshu Capsule, Based on the Combination of HPLC, LC-DAD-MSⁿ, and LC-DAD-ESI-IT-TOF/MS Analyses

Juanjuan Liang,^{1,2} Huimin Gao,^{1,2} Liangmian Chen,^{1,2} Wei Xiao,³
Zhenzhong Wang,³ Yongyan Wang,¹ and Zhimin Wang^{1,2}

¹ Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China

² National Engineering Laboratory for Quality Control Technology of Chinese Herbal Medicine, Beijing 100700, China

³ Jiangsu Kanion Pharmaceut Co. Ltd., Lianyungang 222001, China

Correspondence should be addressed to Huimin Gao; huimin_gao@126.com and Zhimin Wang; zhmw123@263.net

Received 17 April 2014; Revised 28 June 2014; Accepted 30 June 2014; Published 20 July 2014

Academic Editor: Shi-Biao Wu

Copyright © 2014 Juanjuan Liang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chemical profiling is always the first task in the standardization and modernization of Traditional Chinese Medicine. HPLC and LC-MS were employed to find out the common chromatographic peaks in various batches of Tianshu Capsule (TSC) and the contribution of the characteristic peaks from individual herbs to the whole chromatographic profile of TSC sample. A total of 38 constituents were identified in TSC sample based on the comparison of retention time and UV spectra with authentic compounds as well as by summarized MS fragmentation rules and matching of empirical molecular formula with those of published components. This is the first systematic report on the chemical profiling of the commercial TSC product, which provides the sufficiently chemical evidence for the global quality evaluation of TSC products.

1. Introduction

Traditional Chinese Medicine (TCM) is getting more attention all over the world due to its exact clinical practice, especially prescription application, which comprehensively highlights the quintessence of the theory of traditional Chinese medical science. *Da Chuan Xiong Fang* (DCXF), a well-known and extensively used TCM decoction for the treatment of migraine, first appeared in *Xuan Ming Lun Fang*, a famous formula book written by Wansu Liu who lived in Jin Dynasty (1115–1234). It is composed of two herbs, namely, Chuanxiong (*Chuanxiong rhizoma*) and Tianma (*Gastrodiae rhizoma*), with a crude weight ratio of 4 : 1. Eight dosage forms of DCXF such as capsule, tablet, dripping-pill, honeyed pill, oral liquid, and granule, have been authorized to Chinese market. Tianshu Capsule (TSC), as a representative of DCXF preparations, is widely used in clinics for treating the blood stasis type of headache and migraine [1, 2].

Phytochemical and pharmacological investigations showed that phenols, organic acids, phthalides, and nitrogen-containing compounds were the major active ingredients of DCXF [3]. Several qualitative analyses have been reported concerning main types of constituents in DCXF [4–7]. One study described the identification of 17 different constituents in the 50% EtOH extract of DCXF by LC-Q-TOF/MS, containing gastrodin, parishin C, ferulic acid, guanosine, adenosine, palmitic acid, and 11 phthalide compounds [4]. Another similar study identified 3 compounds of Chuanxiong (ferulic acid, senkyunolide I, and senkyunolide H) and 8 constituents of Tianma (gastrodin, s-(4-hydroxybenzyl)-glutathione, parishin, parishin B, parishin C, p-hydroxybenzaldehyde, etc.) by using the HPLC-DAD-MSⁿ coupling technique, respectively [5]. Continuous reports from the second research group confirmed that 10 different compounds, including 6 original substances of Chuanxiong and 4 original ones of Tianma,

were detected in the rat plasma after the gavage of DCXF active components [6, 7]. However, all these investigations mentioned above were carried out based on the samples of the 50% EtOH extract of the mixture of both herbs (4:1) or active components of single crude herb. No systematic reports could be available involving the chemical profiling of the commercial finished products derived from DCXF. TSC was produced from both crude herbs by employing the various pharmaceutical engineering technologies and the complex manufacturing processes such as extraction, concentration, and preparation. The accumulating studies showed that decocting could induce chemical changes of medicinal herbs or combinatorial formula [8]. It is well-known that ferulic acid and some of the phthalides such as *Z*-ligustilide and dimeric phthalide are unstable at high temperature [9, 10]. Therefore, during the preparation of TSC, these thermolabile components may undertake chemical transformation, consequently leading to the difference of chemical compositions of finished products with DCXF decoction. Understanding the chemical profiles of TSC samples would be helpful in selecting suitable chemical markers for the quality control and pharmacokinetic study. In this work, a combination of HPLC, LC-DAD-MSⁿ, and LC-DAD-ESI-IT-TOF/MS analyses was employed to find out and identify the common components in various batches of commercial TSC samples. The contribution of the characteristic peaks from individual herb to the whole chemical profiling of TSC was also discussed. A total of 38 constituents were identified or tentatively characterized, among which the water-soluble compounds with higher polarity from *Gastrodiae rhizoma* are detected in TSC samples for the first time.

2. Materials and Methods

2.1. Materials and Reagents. Five batches of Tianshu Capsules and related crude herbal materials (*Chuanxiong rhizoma* and *Gastrodiae rhizoma*) were provided by Kanion Pharmaceutical (Lianyungang, China). The reference substances of gastrodin (Lot. 110807-200205), 5-hydroxymethyl-2-furfural (5-HMF, Lot. 111626-201007), ferulic acid (Lot. 0773-9607), and *Z*-ligustilide (Lot. 111737-201102) were purchased from the National Institutes for Food and Drug Control (Beijing, China). Parishin B (174972-79-3), parishin C (174972-80-6), and parishin (62499-28-9) were from the collection of Dr. Li Wang, Dalian Institute of Chemical Physics, Chinese Academy of Sciences (Dalian, China). The purity for each of these compounds was over 98% by HPLC assay and their structures were shown in Figure 1. HPLC grade methanol (Fisher, Fair Lawn, NJ, USA) and ultrapure water were used for HPLC analyses. All other chemical reagents were of analytical grade from Beijing Chemical Corporation (Beijing, China).

2.2. Sample Preparation

2.2.1. TSC Sample. 1.0 g of pulverized contents of TSC samples was extracted with aqueous methanol (MeOH-H₂O, 1:1,

25 mL) by ultrasonication (250 W, 40 kHz) for 30 min at room temperature, and the extract was then centrifuged for 10 min at 14800 rpm. A volume of 10 μ L of the supernatant was used for HPLC and LC-DAD-MSⁿ analysis.

2.2.2. Extraction of *Chuanxiong Rhizoma*, *Gastrodiae Rhizoma*, and DCXF. The ethanolic and aqueous extracts of individual herb (*Chuanxiong rhizoma* and *Gastrodiae rhizoma*) and the mixture of both herbs (w/w, 4:1, DCXF) were prepared according to the manufacturing processes of TSC (Figure S1 in the Supplementary Material available online at <http://dx.doi.org/10.1155/2014/580745>) described in the current Chinese pharmacopoeia. The ethanolic and aqueous extracts were diluted with aqueous methanol (MeOH-H₂O, 1:1) to the concentration of 0.05 g·mL⁻¹ and then centrifuged for 10 min at 14800 rpm. Each of the supernatants was used for HPLC and LC-MS analyses.

2.2.3. Reference Solution. Stock solutions with a concentration of about 0.010 mg·mL⁻¹ were prepared by dissolving an accurately weighed amount of each reference substance in aqueous methanol (MeOH-H₂O, 1:1). The mixture of 7 reference solutions was prepared from the stock solutions.

2.3. Qualitative HPLC Analyses of 5 Batches of TSC Samples. The analyses were performed on a Shimadzu HPLC system (Shimadzu, Japan) equipped with a LC-20AT binary pump, a DGU-20A5 degasser, a SIL-20AC autosampler, a CTO-20AC column oven, and a SPD-M20A photodiode array detector. The samples were separated on a Phenomenex Luna C₁₈ column (5 μ m, 4.6 $\times$ 250 mm). The mobile phase consisted of methanol (A) and water containing 0.1% formic acid (B) using a gradient program as follows: 0 min, 15% A; 5 min, 15% A; 55 min, 95% A; 60 min, 95% A. The flow rate was 1.0 mL·min⁻¹ and the column temperature was set at 30°C. The PDA detector recorded UV spectra in the range from 190 nm to 400 nm and HPLC chromatogram was monitored at 276 nm.

2.4. Comparison of Typical TSC Sample and Its Related Crude Herbal Materials as Well as DCXF by HPLC and LC-MS. TSC sample and its related crude herbal material, *Chuanxiong rhizoma* and *Gastrodiae rhizoma* as well as DCXF, were analyzed under the same chromatographic conditions by HPLC and LC-MS to find the contribution of individual herb to the whole chemical profile of TSC sample. The HPLC system was the same as those in Section 2.3. LC-MS analyses were performed using an Agilent 6130 Quadrupole LC-MS (Agilent, Waldbronn, Germany) connected to an Agilent 1200 HPLC system (Agilent, Waldbronn, Germany). The parameters for MS analysis in the positive and negative ion mode were as follows: nebulizer, 35 psi; ionization voltage, 3500 V; dry temperature, 350°C; flow rate of carrier gas, 9.0 L·min⁻¹. Full-scan mass spectra were acquired in the range of 100–800 *m/z*.

2.5. LC-DAD-ESI-IT-MSⁿ Analysis of Typical TSC Sample. To comprehensively identify the chemical constituents in

TSC sample by the fragmentation rules, a LC-DAD-ESI-IT-MSⁿ experiment was performed using an Agilent 6320 ion-trap spectrometer (Agilent, Waldbronn, Germany) connected to an Agilent 1200 HPLC system (Agilent, Waldbronn, Germany). The HPLC conditions were the same as those described in Section 2.3. The LC effluent was introduced into an electrospray ionization source after a postcolumn split ratio of 2:1. The parameters for MS analysis in the positive ion mode were as follows: nebulizer, 45 psi; ionization voltage, 4000 V; dry temperature, 350°C; flow rate of carrier gas, 12.0 L·min⁻¹. Full-scan mass spectra were acquired in the range of 100–800 *m/z*. The optimized parameters for MS/MS analysis were as follows: collision energy, 1.5 V; nitrogen was used as the collision gas. MSⁿ spectra of pure substances were obtained using the same parameters as mentioned above.

2.6. LC-DAD-ESI-IT-TOF/MS of Analysis of Typical TSC Sample. To confirm the elemental composition of precursor ions and their fragments with high-accurate mass, a LC-ESI-IT-TOF/MS experiment was performed on a Shimadzu LC-MS-IT-TOF instrument equipped with a Shimadzu UFLCXR HPLC system (Shimadzu, Kyoto, Japan). The HPLC system consisted of a CBM-20A controller, two LC-20AD binary pumps, an SPD-M20A diode array detector, an SIL-20AC autosampler, a CTO-20A column oven, and a DGU-20A3 degasser. The HPLC conditions were the same as those for HPLC-DAD-ESI-MSⁿ analysis. The LC effluent was directed into the ESI source as a rough split ratio of 3:1. The optimized MS conditions were as follows: positive and negative ion mode; electrospray voltage, +4.5 kV/–3.5 kV; detector voltage, 1.65 kV; curved desolvation line (CDL) temperature, 200°C; heat block temperature, 200°C; nebulizing gas (N₂), 1.5 L·min⁻¹; drying gas (N₂), 10 L·min⁻¹; scan range, *m/z* 100–1100 for MS¹, 100–800 for MS², and 100–500 for MS³. The ultrahigh purity argon was used as the collision gas for collision-induced dissociation (CID) experiments, and the collision energy was set at 50% for MS² and MS³; ion accumulated time was 30 ms. The MSⁿ data were collected in an automatic mode and the software could automatically select precursor ions for MSⁿ analysis according to criteria settings. Accurate mass determination was corrected using the external standard method. The data acquisition and analysis were performed by LC-MS Solution Version 3.6 software (Shimadzu, Kyoto, Japan).

3. Results and Discussion

3.1. Qualitative Analyses of TSC and Its Related Crude Herbal Materials by HPLC and LC-MS. Under the HPLC conditions as described in the current Chinese Pharmacopoeia [1], 5 batches of TSC samples, together with the reference compounds, were examined and their HPLC chromatograms were shown in Figure S2. High similarity in the number, type, and amount of chemical constituents was observed in the HPLC profiles of different batches of TSC samples. General chromatographic profile was obtained by Similarity Evaluation System for Chromatographic Fingerprint of Traditional

Chinese Medicine software and characteristic peaks were found in the HPLC profile of each individual sample.

In order to identify the origin of these characteristic peaks from individual herbs, a comparative study was carried out by using various extracts of herbs and TSC samples. Accordingly, the possible individual contribution from the corresponding herbs to the general chromatographic profile was found. Compared with the HPLC profiles of the ethanolic and aqueous extracts of *Chuanxiong rhizoma* and *Gastrodiae rhizoma* (Figure S3), 29 of 38 peaks occurring in HPLC profile of TSC sample were contributed by *Chuanxiong rhizoma* and other 9 peaks came from *Gastrodiae rhizoma* (Figures S4 ~ S10). In addition to the comparison of retention time and on-line UV spectra with those of reference compounds gastrodin, 5-HMF, parishin B, parishin C, parishin, ferulic acid, and Z-ligustilide, the precursor ions obtained by the positive and negative LC-MS (Figure 2) such as [M+H]⁺, [M+NH₄]⁺, [M+Na]⁺, and [M-H][–] further confirmed the contribution of the characteristic peaks from individual herbs to the chromatographic profile of TSC sample (Table 1).

3.2. Identification of Chemical Constituents in TSC by LC-DAD-ESI-IT-MSⁿ and LC-DAD-ESI-IT-TOF/MS. The combination of LC-DAD-ESI-IT-MSⁿ and LC-DAD-ESI-IT-TOF/MS experiments was employed for the identification of chemical constituents in TSC sample, and, as a result, a total of 38 compounds was identified or tentatively characterized. The structures of the identified compounds are shown in Figure 1 and their chromatographic and mass spectrometric data are shown in Tables 2 and 3. The total ion chromatograms (TICs) of TSC sample are shown in Figures S11 and S12, respectively. Among the identified constituents, 7 compounds (2, 3, 5, 6, 7, 9, and 26) were unambiguously identified as gastrodin, 5-HMF, parishin B, parishin C, parishin, ferulic acid, and Z-ligustilide based on the direct comparison of their retention times, UV spectra, and mass spectra with those of the authentic compounds. Furthermore, 31 compounds were tentatively characterized according to their UV spectra, empirical molecular formula, and mass fragmentation pathways as well as their eluted sequence from ODS column reported in the literature [11–14] and acquired in the present experiments.

3.2.1. Fragmentation Characteristic of Reference Compounds.

In the present HPLC and MS conditions, characteristic MS adduct ions were observed for phenolic glycosides, organic acid, and phthalide derivatives. Phenolic glycosides and organic acids could be well-detected in positive and negative ionization mode and adduct ions such as [M+H]⁺, [M+NH₄]⁺, [M+Na]⁺, and [2M+Na]⁺ or [M-H][–] and [M+HCOO][–] were found, whereas phthalides were only detected in positive mode and mainly showed the abundant [M+H]⁺, [M+Na]⁺, and [2M+Na]⁺ ions. The fragmentation characteristic of reference compounds was similar as those described in the literature [11, 14, 15]. For example, gastrodin, the glucoside of *p*-hydroxybenzyl alcohol, mainly showed characteristic product ions at *m/z* 123 and 161 corresponding to the elimination of a molecule of glucose and a molecule of

FIGURE 2: HPLC and TIC of typical TSC sample obtained using an Agilent 6130 Quadrupole LC-MS connected to an Agilent 1200 HPLC system. (a) HPLC (276 nm), (b) (+) TIC, and (c) (-) TIC.

p-hydroxybenzyl alcohol from m/z 285 $[M-H]^-$, respectively. Parishin B and C, the gastrodin derivatives with citric acid, mainly indicated the fragmentation of the ester glucoside bond and the neutral loss of gastrodin residue (268 Da) corresponding to the ion at m/z 459. The ions at m/z 441, 423, 397, and 379 were also observed, which were related to elimination of H_2O and CO_2 from the tertiary alcoholic hydroxyl group and the free carboxylic groups produced by breaking of the ester glucoside bond. Phthalides mainly displayed two pathways: side-chain cleavage with loss of alkenes and ring-opening followed by elimination of H_2O and CO . These series of characteristic ion rules would be beneficial to elucidate the chemical constituents in TSC sample.

3.2.2. Identification of Phenolics Derivatives in TSC Sample. Compounds **1** and **2** gave the same on-line UV spectrum which is in accordance with that of gastrodin. The structure of **2** was identified as gastrodin based on the comparison of retention time, UV spectrum, and characteristic fragment ions with those of authentic compound as well as accurate

molecular weight. The molecular weight of **1** was deduced as 448 from the sodium adduct ion at m/z 471 $[M+Na]^+$ detected in positive mode and deprotonated molecular ion at m/z 447 $[M-H]^-$ in negative mode, respectively. A prominent neutral loss of 162 Da, corresponding to the loss of hexose, and disaccharide residue ions at m/z 323 were observed in MS^2 of the $[M-H]^-$ ion at m/z 447. The loss of 124 Da was assigned to *p*-hydroxybenzyl alcohol just like the characteristic loss of gastrodin. Therefore, compound **1** was identified as elatoside, namely, 6'-(*p*-hydroxybenzyl methyl)-gastrabiose, which was previously isolated from the rhizome of *G. elata* [16].

Compounds **4**, **5**, **6**, and **7** gave the adduct ions $[M+Na]^+$ and $[M+NH_4]^+$ in positive LC-MS and $[M-H]^-$ in negative LC-MS experiments as well as UV spectra, which were similar to those of gastrodin derivatives. Compounds **5** and **6** had the same $[M-H]^-$ ions at m/z 727, which produced the prominent fragment ion at m/z 459 in the MS^2 , due to loss of gastrodin residue (268 Da) as well as other ions at m/z 441, 423, 397, and 379. Combining with retention time and addition of reference substances, **5** and **6** were identified as parishin B and C. Similarly, compound **4** was assigned to parishin E

TABLE 1: Retention time (t_R), UV, and LC-MS data of the identified compounds in Tianshu Capsule and related crude materials.

Number	t_R /min	UV λ_{max} /nm	MW	$[M - H]^-$	$[M + H]^+$	$[M + NH_4]^+$	$[M + Na]^+$	$[2M + Na]^+$	$[M + HCOO]^-$	Tianma	Chuanxiong	Identified compounds
2	5.403	221, 276	286			304			331	+	-	Gastrodin
3	7.736	230, 283	126		127	144	149			+	-	5-HMF
4	15.579	225	460	459		478	483			+	-	Parishin E/G
5	20.691	221, 272	728	727		746	751			+	-	Parishin B
6	22.220	221, 274	728	727		746	751			+	-	Parishin C
8	25.080	218	242	241	243		265	507		-	+	3-Butyl-3,6,7-trihydroxy-4,5,6,7-tetrahydrophthalide
9	25.567	220, 236, 323	194	193	195		217			+	+	ferulic acid
10	27.529	220, 330	226		227		249	475		-	+	Senkyunolide J/N
11	30.667	280	224		225		247	471		-	+	4,5-Dihydro-3,1'-dihydroxy-3-butylphthalide
13	32.436	275	206	205	207					-	+	4-hydroxy-3-butylphthalide
14	34.299	325	396		397					+	+	unidentified
16	38.635	220, 270	222	221	223		245			-	+	Senkyunolide D or 4,7-dihydroxy-3-butylidenephthalide
17	39.502	230, 310	206	205	207		229		435	-	+	Z-6,7-Epoxyiligustilide
18	39.898	280	208	207	209		231		439	-	+	Senkyunolide K/G
19	41.465	220	206	205	207		229		435	-	+	Senkyunolide F
20	42.332	220, 240, 325	192		193		215	407		+	+	Senkyunolide A
21	42.956	226, 280	190		191	208	213	403		-	+	Butylphthalide
22	43.717	218, 270	204	203	205		227	431	249	-	+	Senkyunolide C
23	44.147	210, 285, 330	204	203	205		227	431	249	-	+	Senkyunolide E
24	44.949	220, 270, 330	194		195		217	411		-	+	Cnidilide
26	45.831	205, 280, 328	190		191		213	403		-	+	Ligustilide
27	46.394	220	194		195		217	411		-	+	Neocnidilide
28	46.653	210, 275, 330	188		189	206	211	399		-	+	3-Butylidenephthalide
29	47.231	225, 280, 310	380		381	398	403			-	+	Riligustilide
30	50.042	276	382		383	399	405			-	+	Senkyunolide P
31	50.476	220, 280	380		381	398	403			-	+	3',6,8',3a-Biligustilide
32	50.970	220, 280	380		381	398	403			-	+	Tokinolide B
33	51.065	230, 279	382		383	400	405			-	+	Unidentified
34	51.962	220, 275	380		381		403			-	+	Levistolide A
35	52.267	220, 285	380		381					-	+	3'-Z-3,3',a,8,6'-a-Biligustilide
36	52.693	220, 280	278		279	301	579			-	+	Senkyunolide M
37	53.134	220, 280	278		279	301	579			-	+	Senkyunolide Q
38	53.852	225, 278	382		383	400	405	383		-	+	Unidentified

TABLE 2: Retention time (t_R), UV, and MSⁿ data obtained by LC-DAD-ESI-IT-MSⁿ of the identified compounds in Tianshu Capsule.

Number	t_R /min	Identified compounds	UV $\lambda_{\max}$ /nm	[M + Na] ⁺	[M + H] ⁺	[2M + Na] ⁺	Main product ions	[M – H] [–]	[M + HCOO] [–]	Main product ions
1	6.3	Gastrodin glucose (448)	221, 276	471				447	493	323[M – H-C ₇ H ₈ O ₂] [–] , 285[M – H-gluc] [–] , 179
2	6.3	Gastrodin (286)	220, 269	309			185[M + Na-C ₇ H ₈ O ₂] ⁺	285	331	161[M – H-C ₇ H ₈ O ₂] [–] , 123[M – H-gluc] [–]
3	8.1	5-HMF (126)	230, 283		127		109[M + H-H ₂ O] ⁺	125		459, 441, 423, 397, 379, 217
5	20.3	Parishin B (728)	221, 272	751			483[M + Na-268] ⁺ , 215[483-268] ⁺	727		459, 441, 423, 397, 379, 217
6	21.8	Parishin C (728)	221, 274	751			483[M + Na-268] ⁺ , 215[483-268] ⁺	727		727[M – H-268] [–]
7	23.4	Parishin (996)	221, 271					995		
9	26.0	Ferulic acid (194)	220, 236, 323		195		177[M + H-H ₂ O] ⁺ , 145[177-CH ₃ OH] ⁺ , 209[M + H-H ₂ O] ⁺ , 191[M + H-2H ₂ O] ⁺ , 163[M + H-2H ₂ O-28] ⁺			
10	27.4	Senkyunolide I/N (226)	220, 330	249		475	207[M + H-H ₂ O] ⁺ , 189[M + H-2H ₂ O] ⁺ , 165, 121			
11	30.4	4,5-Dihydro-3,1'-dihydroxy -3-butylphthalide (224)	280	247			207[M + H-H ₂ O] ⁺ , 133[189-56] ⁺			
12	31.6	Senkyunolide I/H (224)	276	247			271[M + H-H ₂ O-28] ⁺ , 243			
15	37.0	Unidentified (316)	230, 276, 280	339	317		189[M + Na-H ₂ O] ⁺ , 171[189-H ₂ O] ⁺	315		
17	37.8	Z-6,7-Epoxytigustilide (206)	230	229			191[M + H-H ₂ O] ⁺ , 173[191-H ₂ O] ⁺ , 149[191-42] ⁺ , 135[191-56] ⁺			
18	38.1	Senkyunolide K/G (208)	233, 280	231			175[M + H-H ₂ O] ⁺ , 147, 119, 105			
20	40.2	Senkyunolide A (192)	280	215	193		173[M + H-H ₂ O] ⁺ , 130			
21	40.7	Butylphthalide (190)	232, 275	213	191		173[M + H-H ₂ O] ⁺ , 145[173-28] ⁺ , 130, 117, 105			
24	42.6	Cnidilide (194)	238, 279, 327	217			171[M + H-H ₂ O] ⁺ , 153[171-H ₂ O] ⁺			
25	43.3	E-Ligustilide (190)	281, 327	213			213[2M + Na-190] ⁺ , 191, 173			
26	43.5	Z-Ligustilide (190)	237, 260, 312	213	191		192[M + H-190] ⁺			
28	44.0	3-Butyridenephthalide (188)	230, 277, 326	211	189		213[2M + Na-190] ⁺ , 191[M + H-190] ⁺ , 145, 117			
29	47.4	Riligustilide (380)	275	403	381		213[2M + Na-190] ⁺ , 191[M + H-190] ⁺			
30	47.5	Senkyunolide P (382)	278	405	383		193[M + H-190] ⁺			
31	47.8	3',6,8',3a-Biligustilide (380)	278, 363	403	381		213[2M + Na-190] ⁺ , 191[M + H-190] ⁺ , 145, 117			
32	48.0	Tokimolide B (380)	278	403	381		173[191-H ₂ O] ⁺ , 191[M + H-190] ⁺ , 145, 117			
33	48.2	Unidentified (382)	230, 279	405	383		245[M + Na-56] ⁺ , 189, 171			
34	48.5	Levistolide A (380)	276	403	381		245[M + Na-56] ⁺ , 189, 171			
35	48.8	Senkyunolide O (380)	278	403	381					
36	49.0	Senkyunolide M (278)	279	301	279					
37	49.4	Senkyunolide Q (278)	278	301	279					
38	49.9	Unidentified (382)	225, 278	405	383					

TABLE 3: Retention time (t_R) and MS data obtained by LC-DAD-ESI-IT-TOF/MS of the identified compounds in the sample of Tianshu Capsule.

Number	t_R /min	Identified compounds	Formula	Mea. mass/ m/z	Calc. mass/ m/z	Error/ppm	Other precursor ions	Main product ions
3	7.6	5-HMF (126)	$C_6H_6O_3$	127.0384[M + H] ⁺	127.0390[M + H] ⁺	-4.72	149.0240[M + Na] ⁺	
5	19.8	Parishin B (728)	$C_{32}H_{40}O_{19}$	727.2123[M - H] ⁻	727.2091[M - H] ⁻	4.40		223.0885[M - H-H ₂ O] ⁻ , 197.1142, 179.1107, 141.0930, 123.0854
6	21.5	Parishin C (728)	$C_{32}H_{40}O_{19}$	727.2132[M - H] ⁻	727.2091[M - H] ⁻	5.64		
8	24.5	3-Butyl-3,6,7-trihydroxy-4,5,6,7-tetrahydrophthalide (242)	$C_{12}H_{18}O_5$	241.1090[M - H] ⁻	241.1081[M - H] ⁻	3.72		
9	25.3	Ferulic acid (194)	$C_{10}H_{10}O_4$	243.1220[M + H] ⁺	243.1227[M + H] ⁺	2.88	265.1060[M + Na] ⁺	209.1177[M + H-H ₂ O] ⁺ , 191.1026[M + H-2H ₂ O] ⁺
10	27.0	Senkynolide I/N (226)	$C_{12}H_{18}O_4$	195.0649[M + H] ⁺	195.0652[M + H] ⁺	-1.54	217.0458[M + Na] ⁺	
11	30.3	4,5-Dihydro-3,1'-dihydroxy-3-butyphthalide (224)	$C_{12}H_{16}O_4$	227.1259[M + H] ⁺	227.1278[M + H] ⁺	-3.37	249.1082[M + Na] ⁺	
12	31.6	Senkynolide I/H (224)	$C_{12}H_{16}O_4$	225.1105[M + H] ⁺	225.1121[M + H] ⁺	-7.11		299.1378[M + H-H ₂ O] ⁺ , 271.1343[M + H-H ₂ O-28] ⁺
15	37.8	Unidentified (316)	$C_{18}H_{20}O_5$	317.1380[M + H] ⁺	317.1384[M + H] ⁺	-1.26	339.1210[M + Na] ⁺	
16	37.8	4,7-Dihydroxy-3-butylenephthalide or senkynolide D (222)	$C_{12}H_{14}O_4$	223.0986[M + H] ⁺	223.0965[M + H] ⁺	9.41	245.0774[M + Na] ⁺	
17	38.7	Z-6,7-Epoxygustilide (206)	$C_{12}H_{14}O_3$	207.1008[M + H] ⁺	207.1016[M + H] ⁺	3.66	229.0824[M + Na] ⁺	189.0856[M + H-H ₂ O] ⁺ , 133.0318
18	39.1	Senkynolide K/G (208)	$C_{12}H_{16}O_3$	209.1167[M + H] ⁺	209.1172[M + H] ⁺	-2.39	231.0974[M + Na] ⁺	191.1091[M + H-H ₂ O] ⁺ , 119.0819
19	40.6	Senkynolide F (206)	$C_{12}H_{14}O_3$	207.1009[M + H] ⁺	207.1016[M + H] ⁺	3.38	229.0815[M + Na] ⁺	189.0911[M + H-H ₂ O] ⁺ , 161.0959
20	41.4	Senkynolide A (192)	$C_{12}H_{16}O_2$	205.0874[M - H] ⁻	205.0870[M - H] ⁻	1.95	411.1821[2M - H] ⁻	161.0976[M - H-44] ⁻ , 106.0421
21	42.1	Butyphthalide (190)	$C_{12}H_{14}O_2$	193.1219[M + H] ⁺	193.1223[M + H] ⁺	-2.07	215.1027[M + Na] ⁺	175.1119[M + H-H ₂ O] ⁺ , 147.1155, 105.0718
22	42.9	Senkynolide C (204)	$C_{12}H_{12}O_3$	191.1061[M + H] ⁺	191.1067[M + H] ⁺	-3.14	407.2196[2M + Na] ⁺	173.0989[M + H-H ₂ O] ⁺ , 145.1049[M + H-H ₂ O-28] ⁺
23	43.4	Senkynolide E (204)	$C_{12}H_{12}O_3$	205.0843[M + H] ⁺	205.0859[M + H] ⁺	-5.85	403.1888[2M + Na] ⁺	187.0763[M + H-H ₂ O] ⁺ , 169.0757[M + H-2H ₂ O] ⁺ , 141.0699[169-28] ⁺
24	44.1	Cnidilide (194)	$C_{12}H_{18}O_2$	195.1372[M + H] ⁺	195.1380[M + H] ⁺	-7.80	227.0663[M + Na] ⁺	177.1323[M + H-H ₂ O] ⁺ , 149.1340[M + H-H ₂ O-28] ⁺
25	44.1	E-Ligustilide (190)	$C_{12}H_{14}O_2$	191.1061[M + H] ⁺	191.1067[M + H] ⁺	-4.10	217.1185[M + Na] ⁺	
26	45.2	Z-Ligustilide (190)	$C_{12}H_{14}O_2$	191.1056[M + H] ⁺	191.1067[M + H] ⁺	-3.14	213.0871[M + Na] ⁺	173.0984[M + H-H ₂ O] ⁺ , 145.0999[M + H-H ₂ O-28] ⁺ , 117.0690
27	45.5	Neocnidilide (194)	$C_{12}H_{18}O_2$	195.1372[M + H] ⁺	195.1380[M + H] ⁺	-5.76	403.1901[2M + Na] ⁺	177.1323[M + H-H ₂ O] ⁺ , 149.1306[M + H-H ₂ O-28] ⁺ , 121.0998
28	45.8	3-Butylenephthalide (188)	$C_{12}H_{12}O_2$	189.0907[M + H] ⁺	189.0910[M + H] ⁺	-4.10	217.1179[M + Na] ⁺	171.0817[M + H-H ₂ O] ⁺ , 153.0800[M + H-H ₂ O-H ₂ O] ⁺ , 143.0882[M + H-H ₂ O-28] ⁺ , 129.0724
29	46.2	Rilgustilide (380)	$C_{24}H_{28}O_4$	381.2058[M + H] ⁺	381.2060[M + H] ⁺	-1.59	211.0720[M + Na] ⁺	193.1212[M/2 + H] ⁺
30	48.9	Senkynolide P (382)	$C_{24}H_{28}O_4$	383.2220[M + H] ⁺	383.2217[M + H] ⁺	-0.52	403.1872[M + Na] ⁺ , 191.1060, 213.0875	
31	49.2	3',6',3a-Bilgustilide (380)	$C_{24}H_{28}O_4$	381.2058[M + H] ⁺	381.2060[M + H] ⁺	-0.52	403.2031[M + Na] ⁺ , 403.1885[M + Na] ⁺ , 191.1091	
32	49.8	Tokinolide B (380)	$C_{24}H_{28}O_4$	381.2037[M + H] ⁺	381.2060[M + H] ⁺	-6.03	403.1878[M + Na] ⁺ , 191.1062	
33	49.9	Unidentified (382)	$C_{24}H_{28}O_4$	383.2220[M + H] ⁺	383.2217[M + H] ⁺		405.2040[M + Na] ⁺	193.1214[M/2 + H] ⁺
34	50.3	Levistolide A (380)	$C_{24}H_{28}O_4$	381.2064[M + H] ⁺	381.2060[M + H] ⁺	1.05	403.1887[M + Na] ⁺ , 191.1054	
35	50.8	Senkynolide O (380)	$C_{24}H_{28}O_4$	381.2061[M + H] ⁺	381.2060[M + H] ⁺	0.26	403.1879[M + Na] ⁺ , 191.1057	191.1051[M/2 + H] ⁺
36	51.4	Senkynolide M (278)	$C_{24}H_{28}O_4$	279.1582[M + H] ⁺			301.1402[M + Na] ⁺ , 579.2952[2M + Na] ⁺	
37	52.0	Senkynolide Q (278)	$C_{24}H_{28}O_4$	279.1596[M + H] ⁺			301.1381[M + Na] ⁺ , 579.2952[2M + Na] ⁺	
38	52.7	Unidentified (382)		383.2217[M + H] ⁺	383.2217[M + H] ⁺	0.00	405.2008[M + Na] ⁺	365.2115, 347.1905, 193.1201[M/2 + H] ⁺

or its positional isomer parishin G with identical molecular mass of 460 [17]. Compound **7** had the molecular mass of 996 and exhibited consecutive loss of gastrodin residue (268 Da), and, therefore, it was identified as parishin, a conjugate of one citric acid and three gasterodins.

3.2.3. Identification of Phthalide Derivatives in TSC Sample. The molecular formula of compound **8**, detected from individual herb *Chuanxiong rhizoma*, was calculated as $C_{12}H_{18}O_5$ by $[M+H]^+$ ion at m/z 243.1220 and $[M-H]^-$ ion at m/z 241.1090 in its LC-IT-TOF/MS experiment. It had the same molecular weight of 242 as those of known compounds, senkyunolide L and 3-butyl-3,6,7-trihydroxy-4,5,6,7-tetrahydrophthalide, present in *Chuanxiong rhizoma*; however, compound **8** could not be senkyunolide L ($C_{12}H_{15}ClO_3$) because both had the different element composition [18]. The fragmentation ion of **8** at m/z 197.1142, which was derived from a retro-Diels-Alder cleavage of the $[M-H-H_2O]^-$ ion at m/z 223.0885, suggested that the structure of **8** was proposed as 3-butyl-3,6,7-trihydroxy-4,5,6,7-tetrahydrophthalide.

Compound **10** displayed $[M+H]^+$ ion at m/z 227.1259, suggesting the molecular formula of $C_{12}H_{18}O_4$. The fragment ions at m/z 209 and 191 in the MS^2 , indicating consecutive loss of H_2O , supported that **10** was a dihydroxylated derivative of ligustilide. UV and MS data of **10** were in accordance with those of senkyunolide J and senkyunolide N, but the stereochemistry information of two hydroxy groups could not be provided. Thus, **10** was tentatively assigned as one of senkyunolide J and senkyunolide N. Compounds **11** and **12** gave the same $[M-H]^-$ ions at m/z 224 and their molecular formula was established as $C_{12}H_{18}O_4$ according to the $[M+H]^+$ ion at m/z 225.1105. However, both constituents had different fragmentation rules. The MS^2 of **11** displayed the fragment ions at m/z 207, 189 and the characteristic ion at m/z 165, which were similar to those of 4,5-dihydro-3,1'-dihydroxy-3-butylphthalide [15], whereas **12** showed elimination of two H_2O followed by side-chain cleavage. Therefore, **11** was deduced as 4,5-dihydro-3,1'-dihydroxy-3-butylphthalide and **12** could be one of senkyunolide I and senkyunolide H [14, 15].

Compounds **13**, **17**, and **19** have the same molecular formula of $C_{12}H_{14}O_3$ and were tentatively characterized as 4-hydroxy-3-butylphthalide, Z-6,7-epoxyligustilide, and senkyunolide F. Compared with monohydroxy phthalide derivatives **13** and **19**, the instable structure of **17** resulted in the ion at m/z 189 as base peak observed in MS^1 , suggesting loss of H_2O from the $[M-H]^-$ ion at m/z 207. Senkyunolide A **20** and Z-ligustilide **26** as main constituents were identified and butylphthalide **21**, senkyunolide C **22**, senkyunolide E **23**, E-ligustilide **24**, and 3-butylidenephthalide **28** were characterized as minor constituents. For the compounds **20**, **21**, **24**, and **26**, the neutral loss of CO (28 Da) and side-chain cleavage (56 Da) from $[M+H-H_2O]^+$ were the common fragmentation rules.

Compound **16** ($C_{12}H_{14}O_3$) was tentatively proposed to 4,7-dihydroxy-3-butylidenephthalide or senkyunolide D. Compound **18** was assigned as senkyunolide K or senkyunolide G. These compounds and their isomers could not be differentiated by available MS data.

Five dimeric ligustilides **29**, **31**, **32**, **34**, and **35**, which produced the protonated ion $[M+H]^+$ at m/z 381, were detected in extracted ion chromatograms. They showed the base peak at m/z 403 $[M+Na]^+$ in MS^1 and the fragment ion at m/z 191 $[M+H-190]^+$ as base peak in MS^2 by the loss of a RDA fragment (145 Da) followed by the loss of H_2O and HCOOH (46 Da). Comprehensively considering the information described in the literature [14], they were tentatively identified as riligustilide, 3',6,8',3a-biligustilide, tokinolide B, levistolide A, and senkyunolide O, respectively. Three compounds, indicating the protonated ion $[M+H]^+$ at m/z 383, were detected in extracted ion chromatograms; however, only senkyunolide P was previously reported in *Chuanxiong Rhizoma*. Thus, compound **30** was tentatively characterized as senkyunolide P and the other compounds (**33** and **38**) were still indefinite based on the available information.

In the modernization of TCM, chemical profiling is always the first task. It is of importance for development of the suitable quality standard and control strategy, study of pharmacokinetics, and interpretation of therapeutic character of TCM [19, 20]. As a marketed product in China, the quality control system of TSC is still to be improved and its pharmacokinetics and action mechanism are not completely clear. Usually, gastrodin, ferulic acid, and 6,7-dihydroxyligustilide are selected as marker compounds for the quality control or the pharmacokinetic study of Tian-shu Capsule [1, 21, 22]. The present investigation provides more chemical information for the selection of the marker compounds and the improvement of quality control. It also tells the pharmacokinetic scientists and ethnopharmacologists which compounds in TSC samples are worth further evaluation. In addition to gastrodin and ferulic acid, more efforts should be made to the group of phthalide derivatives such as major constituents, senkyunolide I/H **12**, 4-hydroxy-3-butylphthalide **13**, senkyunolide A **20**, and Z-ligustilide **26** as well as their dimers. Additionally, it is worth noting that 5-HMF **3**, a potent toxic compound, was found as main peak in the chemical profile of TSC samples. This compound originated from the crude material *Gastrodiae rhizoma* and its content in TSC samples was up to $2.67 \text{ mg} \cdot \text{g}^{-1}$ [23]. If it is necessary to develop its limit standard in TSC product or not, more study are expected. Also, ligustrazine is not detected in TSC sample, even in the extracted ion chromatogram, which could result from its very low amount in crude herbal material (about 0.01~0.02%), although, actually, it is often considered as one of active components in *Chuanxiong rhizoma*.

4. Conclusions

In this study, HPLC analysis was employed to find out the common chromatographic peak in various batches of TSC samples. The contribution of the characteristic peaks from individual herbs to the whole chromatographic profile was discussed based on comparative HPLC and LC-MS analyses. A total of 38 constituents were identified based on the comparison of retention time and UV spectra with authentic

compounds as well as by summarized MS fragmentation rules and matching empirical molecular formula with those of published components. The present investigation provided the good basis for monitoring the manufacturing processes and improving quality control of TSC products.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This research work was supported by China Postdoctoral Science Foundation (2012M510731) and State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process (SKL2010M0204). Meanwhile great thanks are due to Dr. Feng Ji from Shimadzu (China) Co., Ltd., Beijing Office, for measuring the LC-DAD-ESI-IT-TOF/MS experiments.

References

- [1] Chinese Pharmacopoeia Commission, *Chinese Pharmacopoeia*, vol. 1, China Medical Science Press, Beijing, China, 2010.
- [2] W. Xia, M. J. Zhu, Z. Zhang et al., "Effect of Tianshu capsule in treatment of migraine: a meta-analysis of randomized control trials," *Journal of Traditional Chinese Medicine*, vol. 33, no. 1, pp. 9–14, 2013.
- [3] L. Wang, J. M. Zhang, Y. L. Hong, Y. Feng, M. W. Chen, and Y. T. Wang, "Phytochemical and pharmacological review of Da Chuanxiong formula: a famous herb pair composed of Chuanxiong Rhizoma and Gastrodiae Rhizoma for headache," *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 425369, 16 pages, 2013.
- [4] S. M. Ni, D. W. Qian, E. X. Shang, J. A. Duan, J. M. Guo, and Y. P. Tang, "Analysis of Chemical composition of Da chuanxiong Fang by ultra performance liquid chromatography-electrospray ionization quadrupole time of flight/mass spectrometry," *Chinese Journal of Experimental Traditional Medical Formulae*, vol. 16, no. 1, pp. 40–45, 2010.
- [5] L. Shen, X. Lin, S. Liang et al., "Characterization on central ingredients of active components in dachuanxiong fang based on HPLC-DAD-MSn," *Chinese Journal of Experimental Traditional Medical Formulae*, vol. 18, no. 7, pp. 128–134, 2012.
- [6] Y. F. Wei, X. Lin, N. Zhang, and Y. Feng, "UPLC-MS analysis of constituents of *Dachuanxiong Fang* active parts absorbed into blood," *Zhongguo Zhongyao Zazhi*, vol. 36, no. 9, pp. 1245–1248, 2011.
- [7] Y. Wei, N. Zhang, X. Lin, and Y. Feng, "Release characteristics in vitro and pharmacokinetics of *Da Chuanxiong Fang* multiunit drug delivery system in rats," *Acta Pharmaceutica Sinica*, vol. 46, no. 9, pp. 1150–1155, 2011.
- [8] X. L. Zhang, L. F. Liu, L. Y. Zhu et al., "A high performance liquid chromatography fingerprinting and ultra high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry chemical profiling approach to rapidly find characteristic chemical markers for quality evaluation of dispensing granules, a case study on Chuanxiong Rhizoma," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 88, pp. 391–400, 2014.
- [9] X. Z. Zhang, H. B. Xiao, Q. Xu, X. L. Li, J. N. Wang, and X. M. Liang, "Characterization of phthalides in *Ligusticum chuanxiong* by liquid chromatographic-atmospheric pressure chemical ionization-mass spectrometry," *Journal of Chromatographic Science*, vol. 41, no. 8, pp. 428–433, 2003.
- [10] S. Li, R. Yan, Y. Tam, and G. Lin, "Post-harvest alteration of the main chemical ingredients in *Ligusticum chuanxiong* HORT. (Rhizoma Chuanxiong)," *Chemical and Pharmaceutical Bulletin*, vol. 55, no. 1, pp. 140–144, 2007.
- [11] L. Wang, H. B. Xiao, X. M. Liang, and L. Wei, "Identification of phenolics and nucleoside derivatives in *Gastrodia elata* by HPLC-UV-MS," *Journal of Separation Science*, vol. 30, no. 10, pp. 1488–1495, 2007.
- [12] T. Yi, K. S. Leung, G. H. Lu, and H. Zhang, "Comparative analysis of *Ligusticum chuanxiong* and related umbelliferous medicinal plants by high performance liquid chromatography-electrospray ionization mass spectrometry," *Planta Medica*, vol. 73, no. 4, pp. 392–398, 2007.
- [13] R. Yan, S. L. Li, H. S. Chung, Y. Tam, and G. Lin, "Simultaneous quantification of 12 bioactive components of *Ligusticum chuanxiong* Hort. by high-performance liquid chromatography," *Journal of Pharmaceutical and Biomedical Analysis*, vol. 37, no. 1, pp. 87–95, 2005.
- [14] T. Yi, K. S. Leung, G. H. Lu, K. Chan, and H. Zhang, "Simultaneous qualitative and quantitative analyses of the major constituents in the rhizome of *Ligusticum chuanxiong* using HPLC-DAD-MS," *Chemical and Pharmaceutical Bulletin*, vol. 54, no. 2, pp. 255–259, 2006.
- [15] Q. Wu and X. W. Yang, "GC-MS analysis of essential oil from rhizomes of *Ligusticum chuanxiong* cultivated in GAP Base for Chinese Medicinal Materials of China," *China Journal of Chinese Materia Medica*, vol. 33, no. 3, pp. 276–280, 2008.
- [16] L. Ning, *Studies on the constituents of Gastrodia elata and three medicinal plants belongs to Curculigo* [Doctoral thesis], Kunming Institute of Botany, Chinese Academy of Sciences, Kunming, China, 2004.
- [17] L. Wang, H. Xiao, L. Yang, and Z. T. Wang, "Two new phenolic glycosides from the rhizome of *Gastrodia elata*," *Journal of Asian Natural Products Research*, vol. 14, no. 5, pp. 457–462, 2012.
- [18] M. Kobayashi and H. Mitsuhashi, "Studies on the constituents of umbellifera plants X VII structure of three new ligustilide derivatives from *Ligusticum wallichii*," *Chemical & Pharmaceutical Bulletin*, vol. 35, no. 12, pp. 4789–4792, 1987.
- [19] Z. Q. Shi, D. F. Song, R. Q. Li et al., "Identification of effective combinatorial markers for quality standardization of herbal medicines," *Journal of Chromatography A*, vol. 1345, pp. 78–85, 2014.
- [20] Z. Hu, J. Yang, C. Cheng et al., "Combinatorial metabolism notably affects human systemic exposure to ginsenosides from orally administered extract of *Panax notoginseng* roots (Sanqi)," *Drug Metabolism and Disposition*, vol. 41, no. 7, pp. 1457–1469, 2013.
- [21] H. F. Zhang, X. H. Chen, Y. S. Huo, and K. S. Bi, "RP-HPLC simultaneous determination of the contents of gastrodin, ferulic acid and 6,7-dihydroxygustilide in Tianshu capsules under a changed UV wavelengths," *Journal of Shenyang Pharmaceutical University*, vol. 29, no. 6, pp. 443–447, 2012.
- [22] H. Zhang, L. Sun, X. Chen, Y. Huo, B. Yan, and K. Bi, "Simultaneous quantification of 6,7-di-hydroxygustilide and gastrodin in rat plasma by LC-MS: application to pharmacokinetic study of Tianshu capsule," *Latin American Journal of Pharmacy*, vol. 31, no. 1, pp. 112–119, 2012.

- [23] J. J. Liang, H. M. Gao, L. M. Chen et al., "Simultaneous determination of three constituents in Tiansu Capsule by HPLC," *Chinese Journal of Experimental Traditional Medical Formulae*, vol. 19, no. 17, pp. 81–84, 2013.